Dr. Yurong Song has extensive experience in the generation and characterization of various cancer mouse models (including genetically engineered models, syngraft models, and orthotopic models) and primary 2D and 3D organoid cancer cells. Over the past 25 years, she has worked on glioblastoma, mesothelioma, prostate, mammary gland, colon, pancreatic, and lung cancer models and utilized them in testing preclinical vaccines (e.g., neoantigen-based vaccines), chemoprevention agents (e.g., naproxen), and therapeutic drugs (e.g., EGFR and STAT3 inhibitors). Song is pursuing liquid biopsy biomarker research using next-generation sequencing technology for clinical trial monitoring and early cancer detection. She joined the Frederick National Laboratory in 2015 and found it to be a highly collaborative and purpose-driven organization in which to achieve her career goals.
